These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 25769650)
1. [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. Lescut N; Lepinoy A; Schipman B; Cerda T; Guimas V; Bednarek C; Bosset JF Cancer Radiother; 2015 Apr; 19(2):98-105. PubMed ID: 25769650 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210 [TBL] [Abstract][Full Text] [Related]
4. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453 [TBL] [Abstract][Full Text] [Related]
6. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study. Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY Tumori; 2014; 100(2):149-57. PubMed ID: 24852858 [TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163 [TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant-intensified treatment for rectal cancer: time to change? Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339 [TBL] [Abstract][Full Text] [Related]
11. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610 [TBL] [Abstract][Full Text] [Related]
12. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L; Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473 [TBL] [Abstract][Full Text] [Related]
13. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322 [TBL] [Abstract][Full Text] [Related]
15. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865 [TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095 [TBL] [Abstract][Full Text] [Related]
19. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]